Addressing unmet needs in rheumatoid arthritis: the challenge of translating multi-omics into precision therapies
Curr Opin Immunol. 2026 Feb 27;99:102742. doi: 10.1016/j.coi.2026.102742. Online ahead of print. ABSTRACT Rheumatoid arthritis (RA) is a highly heterogeneous chronic systemic inflammatory disease. Approximately 30-40% of patients exhibit an inadequate response to currently available biologic agents and Janus kinase inhibitors. In recent years, rapid advances in multi-omics technologies, including genomics, temporal transcriptomics, proteomics, metabolomics, … Read more